Clinical trials in Madrid – page 49

3 294 clinical trials in Madrid, Spain across 24 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in SpainEnsayosClinicos.es

Madrid at a glance

3 294

clinical trials

Research sites24

Quick filters

3 294 trials in Madrid

Open in trial search

Non-small cell lung cancer

Recruiting

Study comparing RMC-6236 and docetaxel in previously treated patients with advanced or metastatic non-small cell lung cancer who have RAS mutations

Registered drugNo placebo

Study comparing RMC-6236 and docetaxel in previously treated patients with advanced or metastatic non-small cell lung cancer who have RAS mutations

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Docetaxel
Sponsor:Revolution Medicines Inc.

Contact Research Centre

Autoimmune haemolytic anaemia

Recruiting

Study of rilzabrutinib tablets compared to placebo in adults with warm autoimmune hemolytic anemia

Investigational

Study of rilzabrutinib tablets compared to placebo in adults with warm autoimmune hemolytic anemia

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:Rilzabrutinib
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Clear cell renal cell carcinoma

Recruiting

Study of Lutetium-177-PSMA treatment for patients with advanced clear cell kidney cancer who had progression after first or second line therapy

Registered drugNo placebo

Study of Lutetium-177-PSMA treatment for patients with advanced clear cell kidney cancer who had progression after first or second line therapy

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Lutetium (177Lu) Vipivotide Tetraxetan
Sponsor:European Organisation For Research And Treatment Of Cancer

Contact Research Centre

Asthma

Recruiting

Study of PF-07275315 to evaluate its effectiveness and safety in adults with moderate-to-severe asthma who have high levels of eosinophils in their blood

Investigational

Study of PF-07275315 to evaluate its effectiveness and safety in adults with moderate-to-severe asthma who have high levels of eosinophils in their blood

Investigational

Spain

Participants:18–64 years · 65+ years
Sponsor:Pfizer Inc.

Contact Research Centre

COVID-19

Recruiting

Study of ibuzatrelvir alone or combined with remdesivir in adults with COVID-19 who have severely compromised immune systems

Investigational

Study of ibuzatrelvir alone or combined with remdesivir in adults with COVID-19 who have severely compromised immune systems

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:IBUZATRELVIR
Sponsor:Pfizer Inc.

Contact Research Centre

Bullous impetigo+3

Recruiting

Comparing two forms of mupirocin (gel and ointment) for treating impetigo in children: a study of different dosing schedules

Registered drugNo placebo

Comparing two forms of mupirocin (gel and ointment) for treating impetigo in children: a study of different dosing schedules

Registered drugNo placebo

Spain

Participants:0–17 years
Sponsor:Laboratorios Ojer Pharma S.L.

Contact Research Centre

K-ras gene mutation+1

Recruiting

Study of MK-1084, cetuximab and mFOLFOX6 combination compared to mFOLFOX6 with or without bevacizumab for patients with KRAS G12C-mutant advanced colorectal cancer

Registered drugNo placebo

Study of MK-1084, cetuximab and mFOLFOX6 combination compared to mFOLFOX6 with or without bevacizumab for patients with KRAS G12C-mutant advanced colorectal cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Fallopian tube cancer+1

Recruiting

Study of mirvetuximab soravtansine dosing schedules for patients with platinum-resistant advanced ovarian, peritoneal, or fallopian tube cancer with high folate receptor expression

Registered drugNo placebo

Study of mirvetuximab soravtansine dosing schedules for patients with platinum-resistant advanced ovarian, peritoneal, or fallopian tube cancer with high folate receptor expression

Registered drugNo placebo

Spain

Participants:18–64 years
Substances:Prednisolone Acetate
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

B-cell small lymphocytic lymphoma refractory+1

Recruiting

Study of sonrotoclax plus obinutuzumab or rituximab compared to venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

Registered drugNo placebo

Study of sonrotoclax plus obinutuzumab or rituximab compared to venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Obinutuzumab
Sponsor:BeOne Medicines AG

Contact Research Centre

Ovarian cancer

Recruiting

Study of trastuzumab deruxtecan with bevacizumab versus bevacizumab alone as first-line maintenance treatment for patients with HER2-expressing ovarian cancer

Registered drugNo placebo

Study of trastuzumab deruxtecan with bevacizumab versus bevacizumab alone as first-line maintenance treatment for patients with HER2-expressing ovarian cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Daiichi Sankyo Inc.

Contact Research Centre

Neovascular age-related macular degeneration+1

Recruiting

Study of Port Delivery System with ranibizumab given every 36 weeks in patients with neovascular age-related macular degeneration

Registered drugNo placebo

Study of Port Delivery System with ranibizumab given every 36 weeks in patients with neovascular age-related macular degeneration

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Ranibizumab
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Oesophageal adenocarcinoma

Recruiting

Study of rilvegostomig, trastuzumab deruxtecan, and AZD0901 in patients with locally advanced resectable gastroesophageal cancer before and after surgery

InvestigationalNo placebo

Study of rilvegostomig, trastuzumab deruxtecan, and AZD0901 in patients with locally advanced resectable gastroesophageal cancer before and after surgery

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Azd0901
Sponsor:AstraZeneca AB

Contact Research Centre

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Madrid

What the registry says about research in the country

01 Autoimmune and Inflammatory Conditions

Investigating novel treatments for cutaneous lupus erythematosus and immune thrombocytopenia, with studies evaluating new therapeutic approaches to manage these challenging conditions.

Lupus skin manifestations
Platelet disorders
Immune system regulation

Research focuses on improving treatment outcomes and quality of life for patients with autoimmune disorders.

02 Metabolic and Endocrine Disorders

Clinical trials examining innovative therapies for Type 1 Diabetes in combination with weight management, targeting both glycemic control and obesity-related complications.

Diabetes management
Weight control
Metabolic health

Studies aim to develop comprehensive treatment approaches for complex metabolic conditions.

03 Neurological Conditions

Breakthrough research in multiple sclerosis and acute ischemic stroke, exploring new therapeutic options for both pediatric and adult populations.

MS treatment in young patients
Stroke intervention
Neurological recovery

Focus on developing targeted treatments to improve neurological outcomes and patient care.

04 Infectious Disease Prevention

Comprehensive vaccine studies targeting respiratory syncytial virus, influenza, and herpes zoster, with particular attention to vulnerable populations.

Vaccine development
Immune response
Prevention strategies

Research aims to enhance protection against common and serious infectious diseases.

05 Oncology Research

Innovative studies in mantle cell lymphoma and bladder cancer, exploring combination therapies and targeted treatments to improve patient outcomes.

Lymphoma treatment
Bladder cancer therapy
Immunotherapy approaches

Focus on developing more effective and personalized cancer treatments.

Back to Spain All countries